NCT02252835View on ClinicalTrials.gov

Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
GoutHyperuricemia
Interventions
DRUG

Arhalofenate

800 mg once daily orally for four weeks

DRUG

Febuxostat

40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks

DRUG

Arhalofenate

600 mg once daily orally for four weeks

DRUG

Febuxostat

80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks

DRUG

Colchicine

0.6 mg daily

Trial Locations (1)

66212

Vince & Associates Clinical Research, Overland Park

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY